CellCentric Ltd. is a drug discovery company with a foundation in epigenetics. The Company focuses on first-in-class inhibitors of the bromodomain of p300/CBP for the treatment of cancers.In February 2010, CellCentric exclusively licensed a program focused on the discovery, development and commercialization of anticancer therapeutics based on epigenetic targets to Takeda Pharmaceutical. Research would be initiated by Takeda's Research Group, while resulting compound development would be completed by Millennium: The Takeda Oncology Company. CellCentric would be eligible to receive upfront, preclinical and clinical milestone, and royalty payments totalling in excess of $200 million.In February 2010, CellCentric headed a research consortium with the University of Cambridge, University College London, Sigma-Aldrich and The Automation Partnership, to study epigenetic control markers, and measure and monitor epigenetic reprogramming in induced pluripotent (iPS) cells, to evaluate disease modelling and